 The candidate entered phase IIb clinical trials in the end of 2009,, but no further trial have been initiated.Ardea was sold to AstraZeneca in 2012.Fosdevirine (also known as IDX899 and GSK-2248761) is another next generation NNRTI developed by Idenix Pharmaceuticals and ViiV Healthcare.